Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).
Yang Y, Sun J, Wu M, Lau WY, Zheng S, Wang XH, Chen X, Fan J, Dong J, Cai J, Chen M, Chen Y, Cheng Z, Dai C, Shan J, Du CY, Fang C, Hu H, Ji Z, Jia W, Li G, Li J, Li J, Liu C, Liu F, Ma Y, Mao Y, Niu Z, Shen J, Shi J, Shi X, Song W, Sun HC, Tan G, Tao R, Wang X, Wen T, Wu L, Xia J, Xiang BD, Yan M, Ying M, Zhang L, Zhang X, Zeng ZC, Zhang Y, Zhang Z, Zhou J, Zhou C, Zhou J, Zhou L, Zhou X, Zhu J, Zhu Z, Zhang Q, Li Q, Cheng S.
Yang Y, et al.
Liver Cancer. 2022 Jul 20;11(6):511-526. doi: 10.1159/000526038. eCollection 2022 Dec.
Liver Cancer. 2022.
PMID: 36589726
Free PMC article.
Review.
SUMMARY: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular-targeted agents. To better guide the clinical treatment for effective and safe use of immu …
SUMMARY: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking t …